We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+22.77%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.2B
AUM Growth
+$2.02B
Cap. Flow
+$1.08B
Cap. Flow %
8.87%
Top 10 Hldgs %
86.71%
Holding
137
New
4
Increased
21
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.35B
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$11.4M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$9.33M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.29M
5
NGNE icon
Neurogene
NGNE
+$6.99M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$106M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$19.5M
3
ARRY
Array Biopharma Inc
ARRY
+$10.6M
4
EXEL icon
Exelixis
EXEL
+$8.13M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 92.12%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIXC
101
AIxCrypto Holdings Inc
AIXC
$13.2M
$568K ﹤0.01%
3
– –
ADAP
102
DELISTED
Adaptimmune Therapeutics
ADAP
$551K ﹤0.01%
100,000
– –
TARA icon
103
Protara Therapeutics
TARA
$214M
$523K ﹤0.01%
7,465
-2,270
-23% -$170K
BIVV
104
DELISTED
Bioverativ Inc. Common Stock
BIVV
$449K ﹤0.01%
+8,249
New +$406K
DVAX
105
DELISTED
Dynavax Technologies
DVAX
$446K ﹤0.01%
75,000
– –
BDSI
106
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$399K ﹤0.01%
210,021
– –
CCXI
107
DELISTED
ChemoCentryx, Inc.
CCXI
$357K ﹤0.01%
49,064
– –
WINT
108
DELISTED
Windtree Therapeutics Inc
WINT
$291K ﹤0.01%
254,973
– –
TMBR
109
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$191K ﹤0.01%
+25
New +$173K
BGMSP
110
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$83K ﹤0.01%
13,253
– –
BTX.WS
111
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$12K ﹤0.01%
20,084
– –
ABBV icon
112
AbbVie
ABBV
$465B
– –
-1,685,994
Closed -$106M
ALDX icon
113
Aldeyra Therapeutics
ALDX
$97.1M
– –
-142,000
Closed -$760K
ALNY icon
114
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-11,340
Closed -$425K
ARCT icon
115
Arcturus Therapeutics
ARCT
$165M
– –
-333,766
Closed -$4.91M
ENTA icon
116
Enanta Pharmaceuticals
ENTA
$362M
– –
-75,357
Closed -$2.52M
IONS icon
117
Ionis Pharmaceuticals
IONS
$8.93B
– –
-57,140
Closed -$2.73M
NERV icon
118
Minerva Neurosciences
NERV
$191M
– –
-32,351
Closed -$3.04M
PRQR icon
119
ProQR Therapeutics
PRQR
$244M
– –
-212,698
Closed -$1.04M
QURE icon
120
uniQure
QURE
$2.75B
– –
-230,000
Closed -$1.29M
SCYX icon
121
SCYNEXIS
SCYX
$37.4M
– –
-5,845
Closed -$1.49M
TENX icon
122
Tenax Therapeutics
TENX
$393M
– –
-13
Closed -$819K
APTO
123
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-574
Closed -$359K
CNCE
124
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-152,964
Closed -$1.57M
SRRA
125
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-5,000
Closed -$298K
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Baker Bros. Advisors held 137 positions worth $12.2B, up 20% from $10.2B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors deployed $1.08B of net new capital in Q1 2017, opening 4 new positions and adding to 21 existing holdings. Its largest new stake was AnaptysBio: 150,000 shares worth $4.16M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.6M trimmed.

  • Baker Bros. Advisors's largest Q1 2017 buy was AnaptysBio: 150,000 shares worth $4.16M.
  • Baker Bros. Advisors added most to Incyte in Q1 2017, an estimated $1.35B increase.
  • Baker Bros. Advisors's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $10.6M.
  • Baker Bros. Advisors fully exited AbbVie in Q1 2017, selling an estimated $106M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $12.2B portfolio in Q1 2017.
  • Baker Bros. Advisors opened 4 new positions and closed 18 in Q1 2017.
  • Baker Bros. Advisors's portfolio value rose 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.